{"id":"placebo-to-match-sitagliptin","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1201174","moleculeType":"Small molecule","molecularWeight":"523.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo products contain no active pharmaceutical ingredient and are used as control comparators in randomized controlled trials to assess the efficacy of the active drug through blinded comparison. This specific placebo is manufactured to match sitagliptin tablets in appearance, size, and packaging to maintain trial blinding and reduce bias.","oneSentence":"This is an inert placebo formulation designed to match the appearance and administration of sitagliptin for use in blinded clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:26.992Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control comparator in clinical trials evaluating sitagliptin efficacy"}]},"trialDetails":[{"nctId":"NCT05900531","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers","status":"COMPLETED","sponsor":"Kallyope Inc.","startDate":"2022-09-21","conditions":"Obesity","enrollment":60},{"nctId":"NCT03101930","phase":"PHASE4","title":"Cardiovascular Effects of GLP-1 Receptor Activation","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2017-05-01","conditions":"Obesity, PreDiabetes","enrollment":329},{"nctId":"NCT01485614","phase":"PHASE3","title":"Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-10","conditions":"Diabetes Mellitus, Type 2 Diabetes","enrollment":200},{"nctId":"NCT04161430","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2020-01-02","conditions":"Type 2 Diabetes Mellitus","enrollment":766},{"nctId":"NCT00790205","phase":"PHASE3","title":"Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-10","conditions":"Type 2 Diabetes Mellitus","enrollment":14671},{"nctId":"NCT02917031","phase":"PHASE4","title":"Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-01-10","conditions":"Type 2 Diabetes Mellitus, Heart Failure","enrollment":348},{"nctId":"NCT03115112","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-10-12","conditions":"Type 2 Diabetes Mellitus","enrollment":386},{"nctId":"NCT03646721","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2018-08-29","conditions":"Diabetes Mellitus, Type 2","enrollment":108},{"nctId":"NCT01619332","phase":"PHASE1, PHASE2","title":"Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Type II Diabetes","enrollment":220},{"nctId":"NCT01557504","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-18","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT01991197","phase":"PHASE2","title":"Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2014-04","conditions":"Psoriasis, Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02111096","phase":"PHASE2","title":"A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-04","conditions":"Diabetes Mellitus, Type 2","enrollment":174},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":1326},{"nctId":"NCT02791490","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-06-16","conditions":"Type 2 Diabetes Mellitus","enrollment":458},{"nctId":"NCT02647320","phase":"PHASE2","title":"12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2016-01","conditions":"Type 2 Diabetes Mellitus","enrollment":298},{"nctId":"NCT02628392","phase":"NA","title":"A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2015-11","conditions":"Type2 Diabetes Mellitus","enrollment":368},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT01059825","phase":"PHASE2","title":"Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-02-24","conditions":"Diabetes Mellitus, Type 2","enrollment":375},{"nctId":"NCT02226003","phase":"PHASE3","title":"Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-23","conditions":"Type 2 Diabetes Mellitus","enrollment":291},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":"Type 2 Diabetes Mellitus","enrollment":292},{"nctId":"NCT01545388","phase":"PHASE3","title":"Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-23","conditions":"Type 2 Diabetes Mellitus","enrollment":337},{"nctId":"NCT01590771","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":498},{"nctId":"NCT01590797","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-10","conditions":"Type 2 Diabetes Mellitus","enrollment":467},{"nctId":"NCT01177384","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-25","conditions":"Type 2 Diabetes Mellitus","enrollment":380},{"nctId":"NCT01477853","phase":"PHASE3","title":"A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT02284893","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-09","conditions":"Type 2 Diabetes","enrollment":461},{"nctId":"NCT01552694","phase":"PHASE3","title":"Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2012-10","conditions":"Inflammation, Macrophage Infiltration, Cardiovascular Disease","enrollment":38},{"nctId":"NCT01119846","phase":"PHASE2","title":"A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-05","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT02202161","phase":"PHASE2","title":"A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-27","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT01128621","phase":"PHASE2","title":"A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-23","conditions":"Diabetes Mellitus, Type 2","enrollment":66},{"nctId":"NCT01376323","phase":"PHASE2","title":"A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-13","conditions":"Diabetes Mellitus, Type 2","enrollment":92},{"nctId":"NCT01155284","phase":"PHASE2","title":"Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes","status":"COMPLETED","sponsor":"Sanford Health","startDate":"2010-08","conditions":"Type 1 Diabetes","enrollment":70},{"nctId":"NCT00976261","phase":"PHASE1","title":"A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-17","conditions":"Diabetes Mellitus, Type 2","enrollment":72},{"nctId":"NCT01189890","phase":"PHASE3","title":"Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-08-16","conditions":"Type 2 Diabetes Mellitus","enrollment":480},{"nctId":"NCT01076088","phase":"PHASE3","title":"Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-11-15","conditions":"Type 2 Diabetes Mellitus","enrollment":744},{"nctId":"NCT00722371","phase":"PHASE3","title":"MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1615},{"nctId":"NCT00704132","phase":"PHASE1","title":"Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-14","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":57},{"nctId":"NCT01028391","phase":"PHASE3","title":"30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":317},{"nctId":"NCT00730275","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07-18","conditions":"Type 2 Diabetes","enrollment":35},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00397631","phase":"PHASE3","title":"Initial Combination With Pioglitazone Study (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-19","conditions":"Type 2 Diabetes Mellitus","enrollment":520},{"nctId":"NCT00305604","phase":"PHASE3","title":"Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-03-08","conditions":"Type 2 Diabetes","enrollment":206},{"nctId":"NCT00103857","phase":"PHASE3","title":"MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03-17","conditions":"Type 2 Diabetes Mellitus","enrollment":1208},{"nctId":"NCT00086515","phase":"PHASE3","title":"Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06-30","conditions":"Diabetes Mellitus, Type II","enrollment":701},{"nctId":"NCT01098539","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":507},{"nctId":"NCT01081834","phase":"PHASE3","title":"The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-03","conditions":"Diabetes Mellitus, Type 2","enrollment":678},{"nctId":"NCT00838903","phase":"PHASE3","title":"Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1049},{"nctId":"NCT00631488","phase":"PHASE2","title":"A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02","conditions":"Diabetes Mellitus, Type 2","enrollment":146},{"nctId":"NCT00754988","phase":"PHASE3","title":"A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-10","conditions":"Diabetes Mellitus Type 2","enrollment":666},{"nctId":"NCT02949193","phase":"PHASE3","title":"Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2013-05","conditions":"Type 2 Diabetes Mellitus","enrollment":222},{"nctId":"NCT00976937","phase":"PHASE3","title":"24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":319},{"nctId":"NCT00760344","phase":"PHASE2","title":"Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-03","conditions":"Diabetes Mellitus","enrollment":386},{"nctId":"NCT01549964","phase":"PHASE3","title":"Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2012-04","conditions":"Glycemic Control","enrollment":916},{"nctId":"NCT01829464","phase":"PHASE3","title":"TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2013-05","conditions":"Diabetes","enrollment":90},{"nctId":"NCT00337610","phase":"PHASE3","title":"Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":190},{"nctId":"NCT01414920","phase":"PHASE2","title":"Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-08","conditions":"Diabetes Mellitus, Type 2","enrollment":368},{"nctId":"NCT00086502","phase":"PHASE3","title":"Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":"Diabetes Mellitus, Type 2","enrollment":353},{"nctId":"NCT01413542","phase":"NA","title":"Pharmacogenetics of Ace Inhibitor-Associated Angioedema","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2011-11","conditions":"Hypertension, Diabetes Type 2","enrollment":44},{"nctId":"NCT01834274","phase":"PHASE3","title":"Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2013-06","conditions":"Diabetes Mellitus, Type 2","enrollment":96},{"nctId":"NCT00541775","phase":"PHASE3","title":"Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06","conditions":"Type 2 Diabetes Mellitus","enrollment":273},{"nctId":"NCT00087516","phase":"PHASE3","title":"Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":"Diabetes Mellitus, Type 2","enrollment":741},{"nctId":"NCT00289848","phase":"PHASE3","title":"MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-03","conditions":"Type 2 Diabetes Mellitus","enrollment":530},{"nctId":"NCT01984606","phase":"PHASE3","title":"Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2015-01","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT00984867","phase":"PHASE3","title":"Dapagliflozin DPPIV Inhibitor add-on Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-10","conditions":"Type 2 Diabetes","enrollment":833},{"nctId":"NCT00855166","phase":"PHASE3","title":"Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Type 2 Diabetes Mellitus","enrollment":182},{"nctId":"NCT01336738","phase":"PHASE2","title":"Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-06","conditions":"Diabetes, Type 2","enrollment":266},{"nctId":"NCT01106677","phase":"PHASE3","title":"The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1284},{"nctId":"NCT00642278","phase":"PHASE2","title":"An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-04","conditions":"Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent","enrollment":451},{"nctId":"NCT01106690","phase":"PHASE3","title":"The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 2","enrollment":344},{"nctId":"NCT01602003","phase":"PHASE3","title":"Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2009-12","conditions":"Type 2 Diabetes Mellitus","enrollment":425}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo to match sitagliptin","genericName":"Placebo to match sitagliptin","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is an inert placebo formulation designed to match the appearance and administration of sitagliptin for use in blinded clinical trials. Used for Control comparator in clinical trials evaluating sitagliptin efficacy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}